Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-analysis

Journal of the National Cancer Institute

Volumn 102, Issue 7, 2010, Pages 493-501

  Mocellin, Simone ^a   Pasquali, Sandro ^a   Rossi, Carlo R ^a   Nitti, Donato ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; DACARBAZINE; INTERLEUKIN 2; ISOTRETINOIN; MELANOMA VACCINE; PEGINTERFERON ALPHA2B; ANTINEOPLASTIC AGENT;

ARTICLE; ASCO; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCERLIT; CLINICAL TRIAL; COCHRANE LIBRARY; DATA BASE; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG WITHDRAWAL; EMBASE; HUMAN; ISI WEB OF SCIENCE; MEDLINE; MELANOMA; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; SYSTEMATIC REVIEW; ADJUVANT CHEMOTHERAPY; CANCER STAGING; EPIDEMIOLOGY; KAPLAN MEIER METHOD; PATHOLOGY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK; RISK ASSESSMENT; RISK FACTOR; SKIN TUMOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE-FREE SURVIVAL; HUMANS; INTERFERON-ALPHA; KAPLAN-MEIERS ESTIMATE; MELANOMA; NEOPLASM STAGING; ODDS RATIO; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 77950576363     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq009     Document Type: Article

References (69)

1. Wang SQ, Halpern AC. Management of cutaneous melanoma: a public health and individual patient care perspective. Adv Dermatol. 2007;23:81-98.
2. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet. 2005;365(9460):687-701.
3. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351(10):998-1012. (Pubitemid 39166263)
4. Tawbi HA, Kirkwood JM. Management of metastatic melanoma. Semin Oncol. 2007;34(6):532-545.
5. Lui P, Cashin R, Machado M, et al. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev. 2007;33(8):665-680. (Pubitemid 350082665)
6. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer. 2007;109(3):455-464.
7. Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004;54(3):131-149; quiz 182-184. (Pubitemid 38812179)
8. Kirkwood JM, Tarhini AA, Moschos SJ, Panelli MC. Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma. Nat Clin Pract Oncol. 2008;5(1):2-3. (Pubitemid 351512419)
9. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol. 2005;23:307-336. (Pubitemid 40563172)
10. Pestka S. Purification and cloning of interferon alpha. Curr Top Microbiol Immunol. 2007;316:23-37.
11. Moschos S, Kirkwood JM. Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma. Cytokine Growth Factor Rev. 2007;18(5-6):451-458. (Pubitemid 47302841)
12. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995;13(11):2776-2783.
13. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7-17.
14. Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 1998;16(4):1425-1429.
15. Grob JJ, Dreno B, de la Salmoniere P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998;351(9120):1905-1910. (Pubitemid 28297445)
16. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18(12):2444-2458.
17. Cameron DA, Cornbleet MC, Mackie RM, et al. Adjuvant interferon alpha 2b in high risk melanoma-the Scottish study. Br J Cancer. 2001;84(9):1146-1149.
18. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19(9):2370-2380.
19. Cascinelli N, Belli F, MacKie RM, et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet. 2001;358(9285):866-869. (Pubitemid 32900567)
20. Kirkwood JM, Ibrahim J, Lawson DH, et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol. 2001;19(5):1430-1436. (Pubitemid 32202550)
21. Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol. 2004;22(1):53-61. (Pubitemid 41095114)
22. Kleeberg UR, Suciu S, Brocker EB, et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer. 2004;40(3):390-402. (Pubitemid 38121277)
23. Eggermont AM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005;366(9492):1189-1196. (Pubitemid 41393597)
24. Garbe C, Radny P, Linse R, et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective- randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol. 2008;19(6):1195-1201. (Pubitemid 351796347)
25. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372(9633):117-126. (Pubitemid 351952257)
26. Kokoschka EM, Trautinger F, Knobler RM, Pohl-Markl H, Micksche M. Long-term adjuvant therapy of high-risk malignant melanoma with interferon alpha 2b. J Invest Dermatol. 1990;95(suppl 6):193S-197S.
27. Rusciani L, Petraglia S, Alotto M, Calvieri S, Vezzoni G. Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up. Cancer. 1997;79(12):2354-2360. (Pubitemid 27251018)
28. Kerin MJ, Gillen P, Monson JR, et al. Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma. Eur J Surg Oncol. 1995;21(5):548-550.
29. Stadler R, Luger T, Bieber T, et al. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: a controlled, randomised multicentre trial. Acta Oncol. 2006;45(4):389-399. (Pubitemid 43884606)
30. Hauschild A, Weichenthal M, Balda BR, et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol. 2003;21(15):2883-2888. (Pubitemid 46621837)
31. Richtig E, Soyer HP, Posch M, et al. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group. J Clin Oncol. 2005;23(34):8655-8663. (Pubitemid 46211508)
32. Mitchell MS, Abrams J, Thompson JA, et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alfa-2b compared with high-dose interferon alfa-2b for resected stage III cutaneous melanoma. J Clin Oncol. 2007;25(15):2078-2085. (Pubitemid 46972794)
33. Pectasides D, Dafni U, Bafaloukos D, et al. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol. 2009;27(6):939-944.
34. Mohr P, Hauschild A, Enk A, et al. Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: an interim analysis of a randomized phase III study (NCT00226408) [2008 ASCO Meeting abstract 9040]. J Clin Oncol. 2008;26(15S):9040.
35. Hauschild A, Volkenandt M, Tilgen W, et al. Efficacy of interferon alpha 2a in 18 versus 60 months of treatment in patients with primary melanoma of >1.5 mm tumor thickness: a randomized phase III DeCOG trial. [2008 ASCO Meeting abstract 9032]. J Clin Oncol. 2008;26(15S):9032.
36. Kilbridge KL, Cole BF, Kirkwood JM, et al. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol. 2002;20(5):1311-1318.
37. Wheatley K, Ives N, Hancock B, et al. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev. 2003;29(4):241-252. (Pubitemid 37069655)
38. Pirard D, Heenen M, Melot C, Vereecken P. Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis. Dermatology. 2004;208(1):43-48. (Pubitemid 38142333)
39. Eggermont AM, Voit C. Management of melanoma: a European perspective. Surg Oncol Clin N Am. 2008;17(3):635-648, x. (Pubitemid 351699254)
40. Thirlwell C, Nathan P. Melanoma-part 2: management. BMJ. 2008;337:a2488.
41. Bajetta E. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma. Nat Clin Pract Oncol. 2008;5(1):4-5. (Pubitemid 351512420)
42. Ascierto PA, Kirkwood JM. Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med. 2008;6:62.
43. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res. 2007;17(2):117-127. (Pubitemid 46673905)
44. Dummer R, Hauschild A, Jost L. Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(suppl 2):ii86-ii88.
45. Verma S, Quirt I, McCready D, et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer. 2006;106(7):1431-1442.
46. National Comprehensive Cancer Network (NCCN). Melanoma. http://www.nccn.org. Accessed March 2009.
47. Lens M. Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease. Dermatol Ther. 2006;19(1):9-18.
48. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354(9193):1896-1900.
49. Sutton A, Abrams K, Jones D, Sheldon T, Song F. Methods for Meta-analysis in Medical Research. Chichester: Wiley; 2000.
50. Alderson P, Green S, Higgins J. Cochrane Reviewers' Handbook (version 4.2.2). Chichester: Wiley; 2004.
51. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815-2834. (Pubitemid 28562978)
52. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. (Pubitemid 47161711)
53. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27(5):335-371. (Pubitemid 15107153)
54. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. (Pubitemid 17189972)
55. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Multiple comparisons within a study. Introduction to Meta-analysis. Chichester: Wiley; 2009:239-242.
56. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Subgroup analysis. Introduction to Meta-analysis. Chichester: Wiley; 2009:149-186.
57. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med. 1999;18(20):2693-2708.
58. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337(8746):867-872.
59. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634. (Pubitemid 27387172)
60. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-1101.
61. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455-463. (Pubitemid 30422636)
62. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10(5):1670-1677. (Pubitemid 38435557)
63. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Power analysis for meta-analysis. Introduction to Meta-analysis. Chichester: Wiley; 2009:257-275.
64. Wheatley K, Ives N, Eggermont A, et al. Interferon-a as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials [2007 ASCO Meeting abstract 8526]. J Clin Oncol. 2007;25(18S):8526.
65. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319(7223):1492-1495.
66. Mathoulin-Pelissier S, Gourgou-Bourgade S, Bonnetain F, Kramar A. Survival end point reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol. 2008;26(22):3721-3726.
67. Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol. 2009;27(1):38-44.
68. Domingo-Domenech J, Castel T, Auge JM, et al. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients. Tumour Biol. 2007;28(5):264-272. (Pubitemid 350165832)
69. Yurkovetsky ZR, Kirkwood JM, Edington HD, et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res. 2007;13(8):2422-2428.